ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,398Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 570

$6.15M Total Retail Price of All Prescriptions

Rank: 1 out of 570

426 Patients Receiving at Least One Drug in Part D
32%Patients 65 Years and Older
43% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 426 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

38% of this provider’s 426 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 2,958 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

50% of this provider’s prescriptions were for brand-name drugs, compared to an average of 52%.

Prescription Price

$427 was the average price of a prescription from this provider, compared to $124 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
NORVIR 694 44 1 122
TRUVADA 644 91 2 127
ISENTRESS 547 87 3 137
ACYCLOVIR 509 82 10 4 124
REYATAZ 342 29 5 172
TESTOSTERONE CYPIONATE 339 41 S3 10 6 173
ATRIPLA 324 31 7 177
VALACYCLOVIR 321 23 10 8 178
PREZISTA 319 33 9 179
ZOLPIDEM TARTRATE 312 50 10 17
CRESTOR 306 64 11 60
LISINOPRIL 278 41 12 11
EPZICOM 248 84 13 199
ANDROGEL 244 36 S3 10 14 184
ATORVASTATIN CALCIUM 240 67 15 20
VIREAD 228 30 16 204
BUPROPION XL 208 45 17 214
INTELENCE 190 33 18 218
GABAPENTIN 186 64 19 25
OMEPRAZOLE 178 31 20 5
LEXIVA 176 17 10 21 227
METFORMIN HCL 171 29 22 14
BUPROPION HCL SR 162 19 23 234
SULFAMETHOXAZOLE-TRIMETHOPRIM 156 11 24 59
TRAZODONE HCL 152 0 25 80
HYDROCODONE-ACETAMINOPHEN 148 55 S3 26 9
AMLODIPINE BESYLATE 141 61 27 7
TAMSULOSIN HCL 137 68 28 37
GEMFIBROZIL 136 13 29 118
SELZENTRY 128 18 10 30 249
KALETRA 126 34 31 252
LOVAZA 121 27 32 153
FENOFIBRATE 121 0 32 109
LAMOTRIGINE 114 17 34 182
LAMIVUDINE 113 0 10 35 269
DIPHENOXYLATE-ATROPINE 112 26 36 206
VIRAMUNE 106 24 10 37 275
ATENOLOL 106 0 37 22
CYMBALTA 103 0 39 93
ZIAGEN 99 33 10 40 280
INSULIN SYRINGE 98 15 41 115
MIRTAZAPINE 87 0 42 65
FINASTERIDE 86 19 43 106
SUSTIVA 86 35 43 287
VIRAMUNE XR 82 12 45 292
EPIVIR 79 0 10 46 294
LYRICA 79 43 46 194
FLUOXETINE HCL 77 16 48 94
LEVOTHYROXINE SODIUM 76 41 49 8
NASONEX 75 19 50 57
FLUCONAZOLE 75 25 50 239
LISINOPRIL-HYDROCHLOROTHIAZIDE 74 23 52 108
OXANDROLONE 70 14 53 306
PRAVASTATIN SODIUM 69 0 54 43
TESTIM 68 0 55 312
ABACAVIR 67 19 10 56 313
TRICOR 67 13 56 151
HYDROCHLOROTHIAZIDE 66 0 58 26
NEVIRAPINE 62 22 10 59 317
SEROSTIM 62 0 59 317
EGRIFTA 60 13 61 325
DAPSONE 56 0 62 337
ZETIA 53 0 63 135
SIMVASTATIN 53 41 63 6
PROAIR HFA 52 0 65 4
CITALOPRAM HBR 52 18 65 82
ZOLPIDEM TARTRATE ER 51 17 67 352
CLOPIDOGREL 51 25 67 48
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 18, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.